DELIVER Results – Scott D. Solomon, MD

Investigator Scott D. Solomon, MD recaps the results of the DELIVER trial, which found that among individuals with heart failure and a mildly reduced or preserved ejection fraction, dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular death.

Related posts:

DELIVER Commentary – Clyde Yancy, MD, FAHA Natural Synergy: Health Product With Epic 75-90% Comms & $1.89 EPCs! Pooled Analysis DAPA HF and DELIVER – Pardeep S. Jhund, MBChB, MSc, PhD Qigong for happiness, health and vitality